Novanta vs Ultralife
NOVT and ULBI side by side, both in electronic and other electrical equipment and components, except computer equipment. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NOVT and ULBI compare
Novanta is the larger company, worth 17 times as much as Ultralife ($4.4B against $261M).
Novanta grew revenue faster over the last twelve months (7.6% versus 4.7% for Ultralife).
Novanta keeps more of each dollar of sales as profit, with a net margin of 6.0% compared with −3.5% at Ultralife.
Novanta scores higher on the StockData Score (12 against 6 for Ultralife), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NOVT | ULBI |
|---|---|---|
| Size and price | ||
| Market cap | $4.4B | $261M |
| Share price | $115.33 | $15.67 |
| Change, 1 year | 11.1% | 182% |
| Change, 5 years | −28.0% | 183% |
| Beta (5Y) | 1.72 | 0.53 |
| Employees | 3,000 | 678 |
| StockData Score | ||
| Total score | 12 (better) | 6 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 73.9× | – |
| P/S | 4.2× | 1.4× (better) |
| P/B | 2.7× | 2.0× (better) |
| EV/EBITDA | 25.2× | – |
| P/FCF | 38.2× (better) | 129× |
| FCF yield | 2.6% (better) | 0.78% |
| Fair value | $111.19 | $7.90 |
| Margin of safety | −3.7% (better) | −98.4% |
| Growth | ||
| Revenue growth (TTM) | 7.6% (better) | 4.7% |
| Revenue growth, 5Y average | 10.7% | 12.2% (better) |
| Net income growth (TTM) | 0.66% (better) | −305% |
| EPS growth (TTM) | −8.2% | – |
| EPS growth, 5Y average | 3.3% | – |
| Profitability | ||
| Gross margin | 44.5% (better) | 24.4% |
| Operating margin | 9.0% (better) | −4.5% |
| Net margin | 6.0% (better) | −3.5% |
| FCF margin | 11.1% (better) | 1.1% |
| Return on equity | 5.1% (better) | −4.8% |
| Return on invested capital | 6.3% (better) | −3.8% |
| Financial health | ||
| Debt / equity | 0.14 (better) | 0.34 |
| Net debt / EBITDA | −3.18 | – |
| Current ratio | 4.57 (better) | 2.87 |
| Altman Z-score | 6.35 (better) | 2.75 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 1.2% | – |
| Shareholder yield | 1.2% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 119% | 32.1% |
| Held by insiders | 0.73% | 41.4% |
| Insider net buying, 12 months | −$11.6M | $2.2M (better) |
| Short interest, % of float | – | 0.66% |
Go deeper
- NOVT stock overview
- NOVT income statement
- NOVT valuation and score
- ULBI stock overview
- ULBI income statement
- ULBI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.